Second, we were unable to demonstrate the intra-patient variability of the EGFR or KRAS mutations between primary lesions and metastatic lesions, because the tests for EGFR and KRAS mutations were performed in either the primary tumor or metastatic tumor sample from each patient. Here, KRAS is linked to metastatic neoplasm.